Lifeward Announces 1-for-12 Reverse Stock Split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy LFWD?
Source: stocktwits
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFWD
Wall Street analysts forecast LFWD stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.430
Low
4.50
Averages
4.50
High
4.50
Current: 6.430
Low
4.50
Averages
4.50
High
4.50
About LFWD
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
- Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
- Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
See More
Lifeward Ltd Earnings Analysis and Strategic Outlook
- Strategic Transaction Strengthens Capital Base: Lifeward Ltd's strategic transaction with Oomed provides significant capital access, thereby reinforcing its financial foundation and laying a solid groundwork for future technology platform development.
- International Market Expansion: The company has made significant progress in international distribution, particularly in Europe, achieving reimbursement coverage for Rewalk with major Medicare insurers, which enhances patient access and strengthens market competitiveness.
- Revenue Decline Challenges: Despite advancements in technological innovation, the company faced a 14% year-over-year revenue decline, indicating financial challenges, particularly as the hybrid sales model in the U.S. has yet to yield expected revenue growth, impacting overall profitability.
- Future Growth Potential: Although specific financial guidance is not currently provided, CEO Mark Grant anticipates maximizing reimbursement coverage within the next 12 to 18 months, supported by a promising 22% year-over-year growth in units sold, indicating strong market demand and growth potential.
See More
Lifeward Ltd. Q4 2025 Earnings Call Insights
- Strategic Transformation: Lifeward is finalizing a partnership with Oramed, expected to provide a $3 million loan and $10 million in convertible note financing upon transaction close, thereby strengthening its financial foundation and driving future innovations.
- Financial Performance: Revenue for 2025 was $22 million, down approximately 14% from $25.7 million in 2024, although ReWalk unit sales increased by 22% year-over-year, indicating potential market demand growth.
- Operational Efficiency Gains: Operating expenses decreased by 25% to $28.1 million, with operating loss narrowing by 33% to $19.7 million, reflecting significant progress in cost control that will aid in achieving positive cash flow in the future.
- Market Outlook: Management did not provide future guidance, emphasizing the significant transformation the company is undergoing; despite analysts expressing concerns about diversification and execution risks, management remains optimistic about long-term growth in its core MedTech business.
See More
Lifeward Reports Q4 2025 Earnings Miss
- Earnings Report Disappointment: Lifeward's Q4 2025 non-GAAP EPS of -$2.85 missed expectations by $1.77, indicating a significant decline in profitability that could negatively impact investor confidence.
- Revenue Decline: The company reported revenue of $5.08 million for Q4, a 32.7% year-over-year decrease from $7.5 million in Q4 2024, highlighting overall sales weakness and necessitating a reassessment of market strategies to regain growth.
- Sales Fluctuations: While revenue from ReWalk personal exoskeletons increased by 20% to $1.8 million, sales of the MyoCycle FES bike plummeted by 90% to $0.1 million, indicating challenges in product portfolio management and the need for enhanced marketing of core products.
- Stock Price Reaction: Following the earnings report, Lifeward's shares fell by 6%, reflecting market concerns about the company's future prospects, potentially prompting management to consider a 1-for-12 reverse stock split to improve share performance.
See More
Lifeward to Announce Q4 Earnings on March 18
- Earnings Announcement Date: Lifeward (LFWD) is set to announce its Q4 earnings on March 18 before market open, with a consensus EPS estimate of -$1.08, reflecting a staggering 184.2% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The consensus revenue estimate stands at $7.87 million, representing a modest 4.2% year-over-year growth, suggesting some market demand that could lay the groundwork for future recovery despite the overall weak performance.
- Historical Performance Review: Over the past two years, Lifeward has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting the company's struggles in achieving profitability and revenue growth, which may impact investor confidence.
- Stock Split Plan: Lifeward plans to implement a 1-for-12 reverse stock split, aimed at increasing the share price and improving market perception, which could attract more investor attention, but may also raise concerns about the company's financial health.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
- Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
- Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
See More
Lifeward Ltd Earnings Analysis and Strategic Outlook
- Strategic Transaction Strengthens Capital Base: Lifeward Ltd's strategic transaction with Oomed provides significant capital access, thereby reinforcing its financial foundation and laying a solid groundwork for future technology platform development.
- International Market Expansion: The company has made significant progress in international distribution, particularly in Europe, achieving reimbursement coverage for Rewalk with major Medicare insurers, which enhances patient access and strengthens market competitiveness.
- Revenue Decline Challenges: Despite advancements in technological innovation, the company faced a 14% year-over-year revenue decline, indicating financial challenges, particularly as the hybrid sales model in the U.S. has yet to yield expected revenue growth, impacting overall profitability.
- Future Growth Potential: Although specific financial guidance is not currently provided, CEO Mark Grant anticipates maximizing reimbursement coverage within the next 12 to 18 months, supported by a promising 22% year-over-year growth in units sold, indicating strong market demand and growth potential.
See More
Lifeward Ltd. Q4 2025 Earnings Call Insights
- Strategic Transformation: Lifeward is finalizing a partnership with Oramed, expected to provide a $3 million loan and $10 million in convertible note financing upon transaction close, thereby strengthening its financial foundation and driving future innovations.
- Financial Performance: Revenue for 2025 was $22 million, down approximately 14% from $25.7 million in 2024, although ReWalk unit sales increased by 22% year-over-year, indicating potential market demand growth.
- Operational Efficiency Gains: Operating expenses decreased by 25% to $28.1 million, with operating loss narrowing by 33% to $19.7 million, reflecting significant progress in cost control that will aid in achieving positive cash flow in the future.
- Market Outlook: Management did not provide future guidance, emphasizing the significant transformation the company is undergoing; despite analysts expressing concerns about diversification and execution risks, management remains optimistic about long-term growth in its core MedTech business.
See More
Lifeward Reports Q4 2025 Earnings Miss
- Earnings Report Disappointment: Lifeward's Q4 2025 non-GAAP EPS of -$2.85 missed expectations by $1.77, indicating a significant decline in profitability that could negatively impact investor confidence.
- Revenue Decline: The company reported revenue of $5.08 million for Q4, a 32.7% year-over-year decrease from $7.5 million in Q4 2024, highlighting overall sales weakness and necessitating a reassessment of market strategies to regain growth.
- Sales Fluctuations: While revenue from ReWalk personal exoskeletons increased by 20% to $1.8 million, sales of the MyoCycle FES bike plummeted by 90% to $0.1 million, indicating challenges in product portfolio management and the need for enhanced marketing of core products.
- Stock Price Reaction: Following the earnings report, Lifeward's shares fell by 6%, reflecting market concerns about the company's future prospects, potentially prompting management to consider a 1-for-12 reverse stock split to improve share performance.
See More
Lifeward to Announce Q4 Earnings on March 18
- Earnings Announcement Date: Lifeward (LFWD) is set to announce its Q4 earnings on March 18 before market open, with a consensus EPS estimate of -$1.08, reflecting a staggering 184.2% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The consensus revenue estimate stands at $7.87 million, representing a modest 4.2% year-over-year growth, suggesting some market demand that could lay the groundwork for future recovery despite the overall weak performance.
- Historical Performance Review: Over the past two years, Lifeward has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting the company's struggles in achieving profitability and revenue growth, which may impact investor confidence.
- Stock Split Plan: Lifeward plans to implement a 1-for-12 reverse stock split, aimed at increasing the share price and improving market perception, which could attract more investor attention, but may also raise concerns about the company's financial health.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
